Fresenius Medical Care Deutschland Gmbh

Mdc Max-delbruck-centrum Fur Molekulare Medizin Berlin-buch

Fresenius Medical Care Affina Gmbh

Mucos Pharma Gmbh & Co.

Marlyn Nutraceuticals Inc

Max-delbruck-centrum Fur Molekulare Medizin

Rudolf Kunze

Gerd Wallukat

Peter Rosenthal

Richard Straube

Wolfgang Rönspeck

Karl Ransberger

Gerhard Stauder

Martin Herrmann

Reinhard Voll

Ralf Egner

Dirk Winkler

Manuela Dierenfeld

Joachim Lehmann

Friedrich-Wilhelm Dittmar

Anselm JÜNEMANN

Ursula Schlötzer

A peptide having an EDof less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular &#x3b1;1 loop 2 or &#x3b2;2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of &#x3b3;-secretase activity, an increased release of &#x3b2;-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the EDvalue is measured by bioassay.

Peptides having binding affinity to an antibody which recognizes an epitope on an &#x3b1;1 loop 2 or &#x3b2;2 loop 1 of an adrenoreceptor

A peptide having an EDof less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular &#x3b1;1 loop 2 or &#x3b2;2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of &#x3b3;-secretase activity, an increased release of &#x3b2;-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the EDvalue is measured by bioassay.

Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence:R-X01-X02-X03-X04-X05-X06-X07-X08-X09-X10-X11-X12-X13-R.These peptides have a high affinity for immunoglobulins. Applications of the peptides according to the invention are also described.

Peptides, the production and use thereof for binding immunoglobulins

Peptides which bind auto-antibodies being in a causally pathological relationship with dilatative cardiomyopathy are described. The peptides may be bound, for example, to a solid phase. Auto-antibodies can be removed by treating blood of patients suffering from DCM with the peptides according to the invention.

Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (DCM)

A fractionated, water-soluble, readily absorbable, low molecular weight beta-glucan is usable as an immune-modulator in the mammalian system. A method is disclosed, which produces a fractionated beta-glucan that is water-soluble and has a molecular weight between 1,000 Daltons-30,000 Daltons (1 kD-30 kD) adaptable to affect changes in the immune responses in mammalian systems.

Water-soluble low molecular weight beta-glucans for modulating

The present invention relates to the use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women in need thereof with habitual idiophathic abortion in their anamneses.

Use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in

Growing community of inventors

Berlin, Germany

Rudolf Kunze